Clinical validation of the quantitative Siemens SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers

SUPPLEMENTAL MATERIAL

Supplemental Tables

Supplemental Table S1. Characteristics of 134 COVID-19 patients (sCVOG - neutralisation assay correlation cohort)

		Absolute	%
Number	n	134	100%
Disease severity	Outpatient	26	19%
	General ward	68	51%
	ICU	31	23%
	Not known	9	7%
Age (years)	min	20	
	max	88	
	median (IQR)	57 (50- 68)	
Sex	female	58	43%
	male	76	57%
Symptom onset	yes	120	90%
known	no	14	10%
Date of first	yes	122	91%
positive PCR known	no	12	9%
Time between symptom onset and PCR (days) ^a	median (IQR)	5 (2-8)	
Time between disease onset and blood draw (days) ^b	median (IQR)	63 (54-74)	

^a Refers to the first positive SARS-CoV-2 PCR of the patient; ^b refers to the representative sample used in the sensitivity analysis. Abbreviations: IQR, interquartile range, PCR, polymerase chain reaction.

given by the manufacturer's package inserts.

Attribute	SARS-CoV-2 lgG (sCOVG)	SARS-CoV-2 IgG (COV2G)
Manufacturer	Siemens	Siemens
Version of the package insert	October 2020	June 2020
CE-IVD status	Conform	Conform
EUA status	Granted	Granted
Method	CLIA	CLIA
Platform	ADVIA Centaur XP ^a , XPT	ADVIA Centaur XP ^a , XPT
Specimen type	Serum, plasma (Li-heparin), venipuncture or capillary puncture	Serum, plasma (Li-heparin, K-EDTA)
Sample volume (without dead volume)	40 µl	10 µl
Detected antibodies	IgG	lgG
Solid-phase antigen target	RBD of the S1 protein	RBD of the S1 protein
Result calculation	Index	Index
Interpretation	<1,0: negative ≥1,0: positive 1.00 Index value = 1.00 IU/ml	<1,0: negative ≥1,0: positive
Diagnostic specificity*	99.90% (99.64-99.99, n=1,995)	99.89% (99.61-99.99, n=1,831)
Diagnostic	Days after first PCR-positivity	Days after first PCR-positivity
sensitivity*	0-6: 50.82% (45.58-56.03, n=368)	0-6: 53.49% (42.41-64.23, n=86)
	7-13: 82.47% (76.38-87.55, n=194)	7-13: 93.44% (84.05-98.18, n=61)
	14-20: 91.14% (82.59-96.36, n=79)	≥14:100.00% (91.59-100.00%). n=42
	≥21: 96.41% (92.74-98.54%, n=195)	
Accuracy	Within-day: 2.6-5.8% Between-day: 3.9-6.7%	Within-day: 2.0-4.6% Between-day: 2.8-6.1%

In brackets 95% confidence intervals are shown. Abbreviations: CE-IVD, European Conformity - In Vitro Diagnostic Medical Device; CLIA, chemiluminescence immunoassay; EUA: Emergency Use Authorization; K, potassium; Li, Lithium; n: number of samples tested; RBD: receptor-binding domain; S1: Spike 1 protein of the SARS-CoV-2 virus; ^a indicates the platform used in our study.

Supplemental Table S3. Measurements of the immunoglobulin formulation Privigen®, undiluted and 1:50 diluted.

Privigen	Siemens SARS-CoV-2 IgG (sCOVG)	Siemens SARS-CoV-2 IgG (COV2G)
Undiluted	1.28	1.09
1:50, negative serum	0.00	0.01
1:50, sodium chloride	0.00	0.23

Data indicate the respective results of the raw data indexes of the tests. Privigen® was diluted with negative pre-

pandemic serum or sodium chloride, respectively.

Supplemental Table S4. Diagnostic sensitivity of the two assays stratified for disease

course, age and gender.

		Siemens SARS-CoV-2 IgG (sCOVG)	Siemens SARS-CoV-2 IgG (COV2G)
	sitivity ording to Pl ^a	91.1% (82.6-96.4%)	100.00% (91.59-100.00%)
	Total	178	178
All patients	Positive	161	140
pati	Negative	17	38
All	Sensitivity	90.5% (85.2-94.3)	78.7% (71.9-84.4)
	Total	113	113
e	Positive	105	98
Male	Negative	8	15
	Sensitivity	92.9% (86.5-96.9)	86.7% (79.1-92.4)
	Total	65	65
ale	Positive	56	42
Female	Negative	9	23
	Sensitivity	86.2% (75.3-93.5)	64.6% (51.8-76.1)
	Total	59	59
61	Positive	51	38
18-49	Negative	8	21
	Sensitivity	86.4% (75.0-94.0)	64.4% (50.9-76.5)
	Total	82	82
69	Positive	76	71
50-69	Negative	6	11
	Sensitivity	92.7% (84.8-97.3)	86.6% (77.3-93.1)
	Total	37	37
8	Positive	34	31
70-100	Negative	3	6
	Sensitivity	91.9% (78.1-98.3)	83.8% (68.0-93.8)
Outpatient	Total	65	65
	Positive	55	41
utpa	Negative	10	24
ō	Sensitivity	84.6% (73.5-92.4)	63.1% (50.2-74.7)
-	Total	85	85
Gen. ward	Positive	79	72
	Negative	6	13
Q	Sensitivity	92.9% (85.3-97.4)	84.7% (75.3-91.6)
	Total	28	28
5	Positive	27	27
ICU	Negative	1	1
	Sensitivity	96.4% (81.7-99.9)	96.4% (81.7-99.9)


Sensitivity of the evaluated test-systems including all SARS-CoV-2 PCR-confirmed patients (one sample per patient; the sample \geq 14 days and closest to day 28 after symptom onset was used) and stratified for severity of the disease (outpatient, hospitalised at the general ward, hospitalized at the intensive care unit) as well as age (18-49, 50-69, 70-100 years), respectively. 95% confidence intervals are given in brackets. Abbreviations: PI: package insert. ^a \geq day 14 after PCR-diagnosis.

Supplemental Table S5. Qualitative agreement between the Siemens SARS-CoV-2


IgG and the neutralisation assay.

	Neutralisation assay	
sCOVG	negative	positive
negative	8	2
positive	0	124


Supplemental Figures



Supplemental figure S1. Raw data indexes for the investigated tests Siemens SARS-CoV-2 IgG sCOVG (A) and COV2G (B) of the positive samples (178 samples of different SARS-CoV-2 PCR-confirmed patients) and negative samples (pre-pandemic samples, sCOVG n = 160, COV2G n = 191). The horizontal lines in the dot plots represent the manufacturer's cut off index.



Supplemental Figure S2. Scatter diagram of the quantitative values of the Siemens SARS-CoV-2 IgG sCOVG and the COV2G assays. For illustration purposes, values below 0.2 U/ml or Index, respectively, were set as 0.2. Take note: the upper measurement limit of the COV2G assay is 20.0 Index.



Supplemental Figure S3. Frequency distribution (histograms) of the sample timing

used for sensitivity and quantitative results analyses in the different sub-cohorts.